A catalog of Nearby Poor Clusters of Galaxies

A catalog of 732 optically selected, nearby poor clusters of galaxies covering the entire sky north of $\rm -3^{\circ}$ declination is presented. The poor clusters, called WBL clusters, were identified as concentrations of 3 or more galaxies with photographic magnitudes brighter than 15.7, possessing a galaxy surface overdensity of $10^{4/3}$. These criteria are consistent with those used in the identification of the original Yerkes poor clusters, and this new catalog substantially increases the sample size of such objects. These poor clusters cover the entire range of galaxy associations up to and including Abell clusters, systematically including poor and rich galaxy systems spanning over three orders of magnitude in the cluster mass function. As a result, this new catalog contains a greater diversity of richness and structures than other group catalogs, such as the Hickson or Yerkes catalogs. The information on individual galaxies includes redshifts and cross-references to other galaxy catalogs. The entries for the clusters include redshift (where available) and cross-references to other group and cluster catalogs.Comment: 27 pages, 7 figures, + one 20-page landscape table, accepted for publication in A

Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease

BACKGROUND: Deep brain stimulation (DBS) is an effective and approved therapy for advanced Parkinson’s disease (PD), and a recent study suggests efficacy in mid-stage disease. This manuscript reports the results of a pilot trial investigating preliminary safety and tolerability of DBS in early PD. METHODS: Thirty subjects with idiopathic PD (Hoehn & Yahr Stage II off medication), age 50–75, on medication ≥ 6 months but < 4 years, and without motor fluctuations or dyskinesias were randomized to optimal drug therapy (ODT) (n=15) or DBS+ODT (n=15). Co-primary endpoints were the time to reach a 4-point worsening from baseline in the UPDRS-III off therapy and the change in levodopa equivalent daily dose from baseline to 24 months. RESULTS: As hypothesized, the mean UPDRS total and part III scores were not significantly different on or off therapy at 24 months. The DBS+ODT group took less medication at all time points, and this reached maximum difference at 18 months. With a few exceptions, differences in neuropsychological functioning were not significant. Two subjects in the DBS+ODT group suffered serious adverse events; remaining adverse events were mild or transient. CONCLUSIONS: This study demonstrates that subjects with early stage PD will enroll in and complete trials testing invasive therapies and provides preliminary evidence that DBS is well tolerated in early PD. The results of this trial provide the data necessary to design a large, phase III, double-blind, multicenter trial investigating the safety and efficacy of DBS in early PD